DE602005018037D1 - Verfahren in zusammenhang mit anomalen phosphatmetabolismus assoziierten erkrankungen - Google Patents

Verfahren in zusammenhang mit anomalen phosphatmetabolismus assoziierten erkrankungen

Info

Publication number
DE602005018037D1
DE602005018037D1 DE602005018037T DE602005018037T DE602005018037D1 DE 602005018037 D1 DE602005018037 D1 DE 602005018037D1 DE 602005018037 T DE602005018037 T DE 602005018037T DE 602005018037 T DE602005018037 T DE 602005018037T DE 602005018037 D1 DE602005018037 D1 DE 602005018037D1
Authority
DE
Germany
Prior art keywords
galnac
phosphate metabolism
anomalous
associated diseases
methods relating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005018037T
Other languages
English (en)
Inventor
Eli Sprecher
Reuven Bergman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technion Research and Development Foundation Ltd
Original Assignee
Technion Research and Development Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research and Development Foundation Ltd filed Critical Technion Research and Development Foundation Ltd
Priority claimed from PCT/IL2005/000484 external-priority patent/WO2005108607A1/en
Publication of DE602005018037D1 publication Critical patent/DE602005018037D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602005018037T 2004-05-09 2005-05-08 Verfahren in zusammenhang mit anomalen phosphatmetabolismus assoziierten erkrankungen Active DE602005018037D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL16188604A IL161886A0 (en) 2004-05-09 2004-05-09 Development of inducers of udp-n-acetyl-alphad-galactosamine: polypeptide n-acetylgalactosami-nyltransferase 3(ppgantase
US10/870,030 US7682787B2 (en) 2004-05-09 2004-06-18 Compositions and methods for treating disorders associated with abnormal phosphate metabolism
PCT/IL2005/000484 WO2005108607A1 (en) 2004-05-09 2005-05-08 Compositions and methods for treating disorders associated with abnormal phosphate metabolism

Publications (1)

Publication Number Publication Date
DE602005018037D1 true DE602005018037D1 (de) 2010-01-14

Family

ID=35456599

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005018037T Active DE602005018037D1 (de) 2004-05-09 2005-05-08 Verfahren in zusammenhang mit anomalen phosphatmetabolismus assoziierten erkrankungen

Country Status (4)

Country Link
US (2) US7682787B2 (de)
AT (1) ATE450624T1 (de)
DE (1) DE602005018037D1 (de)
IL (1) IL161886A0 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL161886A0 (en) * 2004-05-09 2005-11-20 Technion Res & Dev Foundation Development of inducers of udp-n-acetyl-alphad-galactosamine: polypeptide n-acetylgalactosami-nyltransferase 3(ppgantase
WO2008017002A2 (en) * 2006-08-01 2008-02-07 The Ohio State University Research Foundation Polymorphisms in genes affecting cns disorders and uses thereof
WO2008143774A2 (en) * 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
US11058675B2 (en) * 2018-03-29 2021-07-13 Carnegie Mellon University Cell-based screening and compounds that modulate GaINAc-transferases
CN117025747B (zh) * 2023-05-16 2024-04-09 山东大学齐鲁医院 检测样本中slc34a3基因变异的试剂在制备筛查低血磷性佝偻病/骨软化症患者的产品的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090036151A (ko) 2000-07-19 2009-04-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 신규 섬유아세포 성장 인자 (ｆｇｆ23) 및 그의 이용 방법
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
IL161886A0 (en) * 2004-05-09 2005-11-20 Technion Res & Dev Foundation Development of inducers of udp-n-acetyl-alphad-galactosamine: polypeptide n-acetylgalactosami-nyltransferase 3(ppgantase

Also Published As

Publication number Publication date
US20080206195A1 (en) 2008-08-28
US20050249718A1 (en) 2005-11-10
ATE450624T1 (de) 2009-12-15
US7682787B2 (en) 2010-03-23
IL161886A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
Hodak et al. Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
IL184678A0 (en) Proteasome inhibitors and methods of using the same
MX2009009624A (es) Droxidopa y composicion farmaceutica de la misma para el tratamiento de la fibromialgia.
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
SG164368A1 (en) Treatment of cancer
DE602005018037D1 (de) Verfahren in zusammenhang mit anomalen phosphatmetabolismus assoziierten erkrankungen
MX2008012479A (es) Tratamiento de enfermedades neurodegenerativas.
IL173722A0 (en) Proteasome inhibitors and methods of using the same
HK1089153A1 (en) Proteasome inhibitors and methods of using the same
TW201129373A (en) Methods and compositions using FGF23 fusion polypeptides
BRPI0408523A (pt) métodos para melhorar um sintoma de esclerose múltipla em um indivìduo, para melhorar esclerose múltipla em um indivìduo mamìfero, para modular uma deficiência de il-10, ou um distúrbio associado com uma deficiência de il-10 em um indivìduo mamìfero, para tratar ou prevenir um distúrbio imunológico em um indivìduo mamìfero e para avaliar o tratamento de esclerose múltipla em um indivìduo mamìfero, composição farmacêutica, e, artigo de manufatura
MX2009005300A (es) Combinacion de un inhibidor de acido desoxirribonucleico polimerasa-alfa y un inhibidor de una cinasa de punto de verificacion para trastornos proliferativos.
MX2014010664A (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
CR20220618A (es) Nuevas proteinas de unión a repeticiones de anquirina y sus usos
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
TW200740808A (en) Inhibiteurs de proteines kinases
ZA202110111B (en) Methods and compositions for treating liver disorders
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
SE0401031D0 (sv) A new glucocorticoid replacement therapy
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
MX2022000712A (es) Moduladores de nlrp3.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition